Skip to main content

Less Recurrence Seen With Endoscopic Submucosal Dissection of Large Lesions

Medically reviewed by Carmen Pope, BPharm. Last updated on Dec 12, 2023.

By Elana Gotkine HealthDay Reporter

MONDAY, Dec. 11, 2023 -- For patients with large benign colonic lesions, endoscopic submucosal dissection (ESD) is associated with reduced recurrence at six months compared with endoscopic mucosal resection (EMR), according to a study published online Dec. 12 in the Annals of Internal Medicine.

Jérémie Jacques, M.D., Ph.D., from Service d'Hepato-Gastro-Enterologie in Limoges, France, and colleagues compared ESD and EMR for large colonic adenomas in a multicenter study involving six French referral centers. Patients with large (≥25 mm) benign colonic lesions referred for resection were randomly assigned to ESD or EMR (178 and 182 patients, respectively). The primary end point was six-month local recurrence.

The researchers found that in the primary analysis set, which included 318 lesions in 318 patients, recurrence occurred after 0.6 and 5.1 percent of 161 ESDs and 157 EMRs, respectively (relative risk, 0.12). After ESD, there were no recurrences observed in R0-resected cases. There were more adverse events after ESD than EMR (35.6 versus 24.5 percent; relative risk, 1.4).

"Patients and physicians should be aware of these study results not only to know when to choose endoscopic resection instead of surgery but also to choose the endoscopic resection strategy that best fits the patient according to the lesion, the acceptance of follow-up colonoscopy, and the available expertise at the center," the authors write.

Abstract/Full Text (subscription or payment may be required)

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted December 2023

Read this next

NCCN: Cancer Drug Shortages Remain a Challenge for Clinicians

FRIDAY, June 28, 2024 -- Almost 90 percent of medical centers report cancer drug shortages, which often impact clinical trials, according to the results of a National...

PIK3CA Could Guide Use of COX-2 Inhibitors in Treatment for Colon Cancer

THURSDAY, June 27, 2024 -- PIK3CA mutational status may be beneficial for predicting response to addition of the cyclooxygenase 2 (COX-2) inhibitor celecoxib to standard adjuvant...

GLP-1 RA Use Linked to Lower Quality of Bowel Preparation

THURSDAY, June 13, 2024 -- The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) for diabetes or obesity is associated with a lower quality of bowel preparation among...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.